
Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.

Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.

Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.

Danish biotech Commit Biologics closed a $60 million seed round led by Ackermans & van Haaren, with AbbVie Ventures and M Ventures joining, to advance COM002, a bispecific antibody that recruits complement rather than T cells to eliminate diseased cells.

FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.

Galinpepimut-S maintenance extended median overall survival to 24.0 vs 14.7 months in transplant-ineligible AML patients in second or later remission.

Mazen Noureddin, MD, MHSc, discusses phase 2 data for GSK’s once-monthly efimosfermin presented at The Liver Meeting 2026, including fibrosis marker results in patients with compensated cirrhosis.

Advances in DNA manufacturing could help overcome emerging constraints and support the next generation of cell and gene therapies.

In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.

FDA issues a complete response letter for Summit Therapeutics’ PD-1/VEGF bispecific ivonescimab in EGFR-mutated non-small cell lung cancer, approves Roche’s obinutuzumab (Gazyva) for primary membranous nephropathy, and approves AstraZeneca’s nanobody C5 inhibitor gefurulimab (Klygefa) for generalized myasthenia gravis.

FDA declined to approve Summit Therapeutics and Akeso’s ivonescimab plus chemotherapy in previously treated EGFR-mutated NSCLC. The agency said the Phase 3 HARMONi trial’s progression-free survival benefit was not enough without a significant overall survival gain.

Obinutuzumab produced complete proteinuria remission in 36.1% of primary membranous nephropathy patients at 2 years vs 5.7% with tacrolimus.

Once-weekly self-injected gefurulimab improved daily-living scores in AChR-positive generalized myasthenia gravis in the 260-patient PREVAIL trial.

J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, and Lilly agreed to buy Calytrix Bio for up to $1.5 billion. Novartis licensed OBI Pharma’s ADC platform, and Seawolf debuted with $100 million and a Sanofi pact.

Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.

FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.

Merck's Dr Dave Maraldo outlines 3 principles for placing manufacturing capacity and how end-to-end ADC supply chains could shift platform thinking.

Donidalorsen sustained a 95% reduction in hereditary angioedema attacks over 2 years, and patients switching from other prophylaxis saw a 71% drop.

FDA has effectively paused its Commissioner’s National Priority Voucher pilot and appears to have halted new complete response letter postings, according to reports. HHS says work on the program is ongoing.

A single 240 mg dose of WVE-007 cut visceral fat while preserving lean mass for 1 year, as Activin E fell by up to 88% across INLIGHT dose groups.

A single dose of Zai Lab’s long-acting bispecific ZL-1503 produced at least 90% inhibition of an atopic dermatitis signaling biomarker through Week 12 in healthy volunteers. Its 40- to 50-day half-life supports a target of dosing every 12 weeks.

In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.

FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.

Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.

FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.

Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.

Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.

Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.

Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.

ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.

ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.